TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma
Status:
Recruiting
Trial end date:
2024-07-15
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the efficacy and safety of TACE combined with
Tislelizumab in patients with advanced intrahepatic cholangiocarcinoma after progression on
first-line systemic therapy.